SFDA Says:’ No defect in Panadol Syrup for Infants and Children in Saudi Arabia

Based on the news circulating about error discovery in the doses on (Panadol syrup for babies and children), SFDA collected random samples from the market to verify that they meet all the conditions and requirements of product registration, and it has not been shown the existence of the defect in the preparations registered in the Saudi market.

SFDA addressed the marketing company, and asked for a detailed report showing how the Saudi market affected by this flaw, the company said the Saudi market was not affected.

Noting that SFDA terms and requirements, differ from what is marketed in other countries, where the manufacturer is required to identify the agen’st name, registration number, and price on the outer packaging, and the company  is not allowed to change the outer packaging information only after the approval of SFDA.

SFDA inspectors in ports verify the product to registration requirements, including the information listed on the outer packaging, and in the event of a any defect in the marketed product, SFDA out of its responsibility, will withdraw the product from the market to ensure the integrity and safety of food and medicine, and prevent their trading, in order to preserve  public health.